Illumina Secures CMS Reimbursement for Oncology Test at $2,989.55, Boosting Precision Medicine Adoption
Event summary
- Illumina's TruSight Oncology Comprehensive test secured CMS reimbursement at $2,989.55 per test, effective January 1, 2026.
- The FDA-approved test profiles over 500 genes in solid tumors, guiding targeted therapies and clinical trial enrollment.
- Reimbursement under PLA code 0543U establishes a predictable payment pathway for Medicare beneficiaries.
- Illumina reported 60% of its sequencing consumables revenue came from clinical customers in 2025.
The big picture
The CMS reimbursement decision removes a key barrier to comprehensive genomic profiling adoption, aligning with the broader shift toward personalized oncology care. Illumina's test is positioned as a gateway to targeted therapies for NTRK and RET gene fusions, supported by partnerships with Bayer and Lilly. The move underscores the growing clinical demand for genomic insights, with Illumina capturing 60% of its sequencing revenue from healthcare applications in 2025.
What we're watching
- Adoption Pace
- How quickly laboratories of all sizes integrate the test into their workflows, expanding precision oncology access.
- Revenue Impact
- Whether the reimbursement decision accelerates Illumina's clinical market growth beyond the 60% revenue share reported in 2025.
- Competitive Response
- How rivals in genomic testing react to Illumina's reimbursement advantage, potentially triggering pricing or innovation shifts.
Related topics